Licensing and Access to Medicines and Vaccines
Date(s) - 22/11/2023
15:00 CET - 16:00 CET
Categories No Categories
Public support, through funding and other form of assistance, is critical for biomedical research & development (R&D) and instrumental in allowing innovative health technologies to reach markets and patients. On many occasions such support, economic or in-kind, is decisive in the early stages of R&D which are then marketed by companies for extortionate prices, generating huge profits. However, it is difficult to ensure a minimum of public return on that investment.
Non-exclusive licensing of publicly generated knowledge is not the prime option favoured by technology transfer officials at universities and research institutions. Extensive research has established that patenting or setting up an independent entity are more appealing choices to develop, upscale or explore further promising results.
HAI and Salud por Derecho invite you to round-table titled “Licensing and access to medicines and vaccines: obstacles and proposals for improving access” discussion to address:
- Ongoing discussions at EU (pharma strategy) and Global (INB) levels regarding access to results from publicly supported R&D
- Trends in dissemination of publicly generated knowledge: licensing strategies, access clauses and societal impact.
- Identify opportunities and obstacles for effective tech transfer from public research institutions
- Gather the inputs of advocates, practitioners and experts on technology transfer, public return and benefit sharing.